Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).

Akebia filed its Investigational New Drug Application with the U.S. Food and Drug Administration (FDA) and recently initiated ...

Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.

Dr. Lal PathLabs (DLPL) has announced the launch of complement testing laboratory, strengthening autoimmune diagnostics. This ...

Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 12% after the company announced the closing of its asset purchase and license agreement with Novo Nordisk for its clinical-stage MASP-3 ...

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. ・The company retired its senior loan ...

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, announced that it has received a milestone payment under its collaboration agreement with Mitsubishi Tanabe Pharma ...

Omeros Corporation (NASDAQ:OMER) surged 12% on Monday after the company confirmed it has officially completed its asset ...

Longhorn Vaccines & Diagnostics ("Longhorn"), a One Health company developing antibodies and diagnostic tools for global public health and zoonosis concerns, today announced compelling new data ...